A piece of news
The event will bring together some 15,000 professionals from 65 countries from 15 to 18 June
A total of 29 companies and 8 institutions from Catalonia will participate in BIO Convention 2015, the most important biotechnology convention in the world held this year in Philadelphia (United States) from 15 to 18 June. The Catalan delegation, coordinated by Biocat, includes pharmaceutical and biotechnology companies, consultancies and service firms, and research organizations.
The BioRegion of Catalonia will have a booth at BIO 2015, in the Spanish pavilion alongside the bioregions of Andalusia and the Basque Country. Seven Catalan companies and organizations will have their own booth: Bcn Peptides, Bioibérica, Laboratorios Salvat, Barcelona Science Park, Som Biotech, Specific Pig and Trifermed.
The Catalan delegation will be made up of a total of 29 companies, including biotechnology firms AB-Biotics, Ability Pharmaceuticals, Bcn Peptides, Bioingenium, Biokit, Bionure, GP Pharm, Intelligent Pharma, Molomics, Oryzon Genomics, Plasma Biotech, Proteodesign, Som Biotech, Specific Pig, Spherium Biomed and Thrombotargets; pharmaceutical companies Almirall, Bioibérica, Esteve, Ferrer Internacional, Gebro Pharma, Grifols Internacional, Laboratorios Salvat, Lacer and Mitelos Bioscience; and service and consultancy companies Grifols Engineering, Insights in Life Sciences, Oficina Ponti and Trifermed.
There will also be 8 institutions: ACCIÓ, the Government of Catalonia business competitiveness agency; Barcelona Clinical Trials Platform (BCTP), an initiative promoted by the Catalan Ministry of Health and Biocat to position Catalonia among the top five European regions to conduct clinical trials; the Polytechnic University of Catalonia (UPC) Biomedical Engineering Research Center; Center for Genomic Regulation (CRG); Institute for Research in Biomedicine of Barcelona (IRB); Barcelona Science Park (PCB); Vall d’Hebron Research Institute (VHIR) and Biocat, which is coordinating the Catalan delegation to BIO for the ninth consecutive year.
Partnering meetings that BIO offers are a privileged international showcase for Catalan companies, some of which will be scouting for licensing deals for their latest developments at the fair.
This is the case of Oryzon Genomics: after signing a collaboration agreement with Swiss pharmaceutical company Roche, will explore potential paths for research collaboration or licensing for its development Ory 2001, for neurodegenerative diseases. SOM Biotech is also looking for license agreements for the last product included into its pipeline, a compound for glioma with potential for other types of cancer.
Likewise, Bcn Peptides will present PARENTIDE, one of the products it is currently developing to treat neuropathic pain.Mitelos Bioscience will present two new dietary supplements in Philadelphia: SNF671, to prevent osteoporosis, and WASHDENT, for oral hygiene.
Another Catalan firm that is gaining presence in the United States is consultancy Trifermed, promoting the new offices they have opened in Boston, which along with the two offices they already have in Canada will help them consolidate their position in North America.
BIO Philadelphia is also a great marketplace for Catalan companies looking to acquire new products. This is the case of Gebro Pharma, which is seeking out products in advanced stages of development to expand its pipeline in pain management, rheumatology, urology, respiratory and other areas; and GP Pharm and Spherium Biomed, which are looking for business opportunities through purchasing licenses.
More information about the BIO Convention 2015 at biocat.cat/en/bio2015